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The present study describes the development and validation of an in vitro dissolution method for evaluation 
to release diclofenac potassium in oral suspension. The dissolution test was developed and validated 
according to international guidelines. Parameters like linearity, specificity, precision and accuracy were 
evaluated, as well as the influence of rotation speed and surfactant concentration on the medium. After 
selecting the best conditions, the method was validated using apparatus 2 (paddle), 50-rpm rotation 
speed, 900 mL of water with 0.3% sodium lauryl sulfate (SLS) as dissolution medium at 37.0 ± 0.5°C. 
Samples were analyzed using the HPLC-UV (PDA) method. The results obtained were satisfactory for the 
parameters evaluated. The method developed may be useful in routine quality control for pharmaceutical 
industries that produce oral suspensions containing diclofenac potassium. 
Uniterms: Dissolution method/development. Dissolution method/validation. Diclofenac potassium/
release in oral suspensions. Oral suspension/quality control. High performance liquid chromatography/
qualitative analysis.
O presente estudo descreve o desenvolvimento e validação de um método de dissolução in vitro para 
avaliação da liberação de diclofenaco potássico suspensão oral. O teste de dissolução foi desenvolvido 
e validado de acordo com as diretrizes internacionais. Parâmetros como linearidade, especificidade, 
precisão e exatidão foram avaliados, bem como a influência da velocidade de rotação e a concentração 
de tensoativono meio. Depois de selecionar as melhores condições, o método foi validado usando o 
aparato 2 (pás), velocidade de rotação de 50 rpm, 900 mL de água com 0,3% de lauril sulfato de sódio 
(LSS) como meio de dissolução a 37,0 ± 0,5 ºC. As amostras foram analisadas pelo método de CLAE-UV 
(PDA). Os resultados obtidos foram satisfatórios para os parâmetros avaliados. O método desenvolvido 
pode ser útil na rotina de controle de qualidade para as indústrias farmacêuticas que produzem suspensões 
orais contendo diclofenaco potássico. 
Unitermos: Método de dissolução/desenvolvimento. Método de dissolução/validação. Diclofenaco 
potássico/liberação em suspensão oral. Suspensão oral/controle de qualidade. Cromatografia líquida de 
alta eficiência/análise qualitativa.
INTRODUCTION
Aqueous solubility of any drug is a key property 
that determines dissolution and absorption, and thus 
bioavailability in vivo. The most widely used test to 
establish the rate of drug release is the dissolution 
test, which is a very important tool to demonstrate 
bioequivalence from batch-to-batch as well as ensuring the 
quality of products and performance after certain changes, 
for instance in the formulation and manufacturing process 
(Azarmir et al., 2007; Frost, 2004; Modi, Tayade, 2007).
For drugs belonging to Biopharmaceutical 
Classification System Class 2, dissolution is the limiting 
step for drug absorption and the dissolution profile must 
be clearly defined and highly reproducible (Oliveira et 
al., 2009). From a biopharmaceutics point of view, a more 
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discriminating dissolution method is preferred because 
the test will indicate possible changes in product quality 
(Vaucher, 2009).
In order to demonstrate that the method is appropriate 
for dissolution test purposes, the parameters of linearity, 
specificity, precision, accuracy, stability and influence of 
the filter type should be evaluated (FDA, 1997; The United 
States Pharmacopeia, 2012).
Diclofenac potassium (DP), benzeneacetic acid 
2-[(2,6-dichlorophenyl)amino], is a non-steroidal 
drug with anti-inflammatory, analgesic and antipyretic 
properties. It is used for rheumatoid arthritis, degenerative 
disease, chronic pain associated with cancer and kidney 
stones and endodontic procedures (Janbroers, 1987; The 
United States Pharmacopeia, 2012).
DP is readily absorbed orally, but the presence of food 
reduces its plasma concentration (Cmax) from about 40% 
to 60%. Unlike sodium salt which has a delayed release, DP 
is formulated to achieve dissolution under acidic conditions 
in the stomach. When compared to other salts, it has higher 
solubility (Jijun et al., 2011; Olson et al., 1997). In the past 
few years several studies have been published concerning 
the determination of DP in pharmaceutical formulations 
(Elkady, 2010; Souza, Tubino, 2005;Naidoo et al., 2009; 
Scallion, Moore, 2009; Sparidans et al., 2008). The USP 
2012, presents the official dissolution test method in vitro 
for DP in tablets, where the dissolution medium utilized 
is simulated intestinal fluid without enzyme, however 
the dissolution test in vitro for DP in oral suspension is 
not listed in any pharmacopoeia and no dissolution test 
for oral suspension has been reported in the literature).
The present study aims to develop and validate a 
dissolution test for DP in oral suspension using a high 
performance liquid chromatographic method (HPLC) to 
determine the release rate of this drug.
MATERIAL AND METHODS
Chemicals and Reagents
Diclofenac potassium reference standard with 99.8% 
purity, was supplied by Farmacopeia Brasileira (2012). 
Two batches, Z0047 and Z0049A, of oral suspension 
(Cataflam®) containing 2 mg/mL of diclofenac potassium 
were obtained from the commercial market. The excipients 
of the pharmaceutical formulation were citric acid, sorbic 
acid, deionized water, strawberry flavor, microcrystalline 
cellulose, sodium cyclamate, hydroxyethyl cellulose, 
propylparaben, methylparaben, propylene glycol, glyceryl 
polyoxyethylene glycol stearate, saccharin sodium. All 
of them were obtained from different local distributors. 
Water was purified using the Millipore® system. All other 
reagents were of analytical grade.
Instrumentation and chromatography conditions
The dissolution test was performed in a PHARMA 
TEST®, PTWS-3E (Hainburg/Germany), digitally 
controlled heater/circulator and multibath (n=8), 
in accordance with general methods (United States 
Pharmacopeia, 2012). The LC system consisted of a 
Shimadzu® (Kyoto, Japan), provide with an LC-20AT 
pump, SIL-20A ht auto sampler, CTO-20AC column 
oven, SPD-M20A PDA detector, CBM-20A system 
controller, and LC solution software was used to quantify 
the samples. The Ultra Basic Denver potentiometer was 
used to determine the pH of all solutions.
Chromatographic separations were achieved using 
a Phenomenex® Luna C8 (150 x 4.6 mm, 5 µm) column 
at 30.0 ± 0.5°C. The mobile phase contained a mixture of 
methanol: buffer phosphate pH 2.5 (70:30 v/v), flow rate 
of 1.0 mL/min, PDA detection at 275 nm. The injection 
volume was 20 µL.
Determinations of sink conditions
The selection of a dissolution medium may be based 
on the solubility data and dosage range of the drug product. 
The sink conditions were determined in different solvents, 
such as: phosphate buffer (pH 6.8 and 7.4) and water with 
sodium lauryl sulphate (0.3%, 0.5%, 1.0% and 1.5%). An 
amount of drug equivalent to the highest dose that can 
be administered was added in 250 mL of each medium. 
After stirring for 24 hours, an aliquot was transferred to a 
volumetric flask and diluted with dissolution medium. The 
drug solubility in each medium was determined in duplicate.
In vitro drug release studies
The dissolution test study with USP apparatus 
2 (50/75 rpm, paddles) was tested to evaluate the best 
conditions. The following procedure was performed for all 
tests to develop this method: an equivalent amount of 10.0 
mg of DP was added to each vessel containing medium that 
was selected based on the solubility data. Syringes were 
utilized to add the product to each vessel. The syringes 
were weighed before and after adding the product, and the 
weight difference was related to product density.
Sample aliquots were withdrawn at 5, 10, 15, 30 and 
60 minutes and replaced with an equal volume of fresh 
medium to maintain a constant total volume. The percentage 
of drug dissolved was determined using the HPLC method.
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Dissolution method validation
Specificity
It was evaluated by preparing a placebo sample of 
oral suspension at the usual concentration. This sample 
was transferred to a vessel (n = 3) with dissolution medium 
and stirred for 2 hours at 150 rpm using paddle and a 
temperature of 37.0 ± 0.5°C. Aliquots of this solution were 
filtered and analyzed using the HPLC method.
Linearity
Aliquots of a 100 µg/mL solution of DP reference 
standard prepared in a dissolution medium were 
transferred to 25 mL volumetric flasks to obtain the final 
concentrations of 2.0, 6.0, 10.0, 14.0 and 18.0 µg/mL. 
Each solution was prepared in triplicate. The linearity was 
evaluated by linear regression analysis, using analysis of 
variance (ANOVA).
Accuracy and precision
Accuracy was evaluated by recovering the amount 
of DP reference substance added to the placebo. Aliquots 
of 0.36, 1.8 and 3.24 mL of the standard solution 
 (5 mg/mL) were added to the vessel containing placebo 
equivalent to a usual concentration and dissolution 
medium at 37.0 ± 0.5 °C, and agitated for 60 minutes with 
a paddle at 50 rpm. The final concentrations were 2.0, 10.0 
and 18.0 µg/mL. The analysis was done in duplicate on 
three days. Repeatability and intermediate precision were 
evaluated based on RSD from the recovery data.
Stability and influence of filter
Dissolution of the sample (n=3) was carried out for 
analysis of stability, under previously selected conditions. 
Samples were collected after 2 hours and injected into the 
HPLC system at 0, 12 and 24 hours. For determination of 
filter interference, samples (n=3) of DP were submitted to 
a dissolution test. After a predetermined time the samples 
were collected and filtered using F. Maia filter (Sample 
A) and centrifuged (sample B). Sample B was used as 
a standard value. This study aims to evaluate whether 
the drug will adsorb on polymeric membrane filter. The 
acceptance criterion for loss by adsorption is a maximum 
of 5.0% (Linderberg et al., 2005).
Evaluation of dissolution profiles
The dissolution profiles were compared using the 
model independent method. The model independent 
approach includes the difference factor (f1) and the 
similarity factor (f2)using equations 1 and 2 respectively: 
f1 = {[Σni=1|Rf – Tt|]/[Σni=1Rf]}x100     (Equation 1)
f2 = 50 x log{[1+ (1/n)Σt=1n (Rt – Tt)2]-0,5x100} (Equation 2)
where n is the number of time points, Rt and Tt are the 
percent dissolved of the reference and test product, 
respectively.
The percent of error is zero when the test and drug 
reference profiles are identical and increase proportionally 
with the dissimilarity between the two dissolution profiles 
(Polli et al., 1996). According to the FDA, 1997, two 
dissolution profiles are declared similar if f1 is between 0 
and 15 and f2 is between 50 and 100. 
RESULTS AND DISCUSSION
Solubility determination
DP BCS (Biopharmaceutical Classification System) 
is class II, and showed low solubility and high permeability. 
Therefore, drugs of this class may show dissolution rate 
as the limiting factor in the absorption process (Fortunato, 
2005; Qureshi, 2006). The solubility test showed that DP 
was soluble in phosphate buffer (pH 6.8 and 7.4) and 
water with sodium lauryl sulphate (0.3%, 0.5%, 1.0% 
and 1.5%), Table I, suggesting that the sink condition was 
satisfied. The term sink condition is defined as the volume 
of medium at least greater than three times that required, 
forming a saturated solution of a drug (The United States 
Pharmacopeia, 2012).
Dissolution profiles of DP in oral suspension
Dissolution tests using a paddle at 75 rpm and 
phosphate buffer (pH 6.8 and 7.4) and water with sodium 
lauryl sulphate (0.3%, 0.5%, 1.0% and 1.5%) were 
evaluated (Figure 1 and 2, respectively).








Buffer solution phosphate (pH 6.8) 98.07 0.34
Buffer solution phosphate (pH 7.4) 99.93 0.72
Water + 0.3% SLS 98.41 0.41
Water + 0.5% SLS 98.05 0.91
Water + 1.0% SLS 98.49 0.37
Water + 1.5% SLS 98.96 0.68
a Mean of two analysis; RSD – Relative Standard Deviation
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For assays utilizing buffer pH 6.8 and 7.4, a very 
rapid drug release was found in the first 5 minutes, 83.98% 
and 96.96% respectively, however for the dissolution 
media using water with SLS at concentrations of 0.3%, 
0.5%, 1.0% and 1.5%, we found that the release rate of the 
drug increases as the surfactant concentration increases in 
the dissolution media.
A rotation speed of 50 rpm (Figure 3) was used to 
retard drug release in dissolution medium containing water 
with SLS 0.3% and 0.5%.
For both dissolution mediums tested the agitation 
speed of the apparatus significantly influenced the rate of 
drug release at each sampling time.
Using water with sodium lauryl sulphate 0.3% 
and apparatus rotating at 50 rpm, a slower, reproducible 
and discriminating release profile was obtained between 
batches when compared with the dissolution medium 
containing water with SLS 0.5%. FDA (1997) recommends 
using the smallest possible amount of surfactant in the 
dissolution medium, because the higher the concentration 
of the surfactant, the greater the difficulty of obtaining a 
correlation. Therefore, the dissolution medium containing 
water with 0.3% SLS was selected to develop the method.
Method validation
Specificity
Specificity was observed by analyzing a placebo 
solution. The chromatograms showed that no interference 
of excipients was observed for the drug retention time 




The linearity was tested in the concentration range 
of 2.0 – 18.0 µg/mL of drug substance. The results 
demonstrate method linearity with a correlation coefficient 
of 0.9999, the slope and y-intercept obtained were 42580 
and 6257, respectively. The analysis by ANOVA showed 
significant regression and non-significant linearity 
deviation (P < 0.05) for the relation between the area of 
the peaks of substance and its concentrations. The results 
were considered acceptable and the linearity curves were 
used to calculate in vitro drug release studies.
FIGURE 1 – Mean dissolution profile of Cataflam® oral 
suspension (n – 12) using phosphate buffer pH 6.8 and 7.4 and 
paddle rotating at 75rpm.
FIGURE 2 – Mean dissolution profile of Cataflam® oral 
suspension (n–12) using water with sodium lauryl sulphate SLS 
(0.3%, 0.5%, 1.0% and 1.5%) and paddle rotating at 75 rpm.
FIGURE 3 – Mean dissolution profile of Cataflam® oral 
suspension (n–12) using water with sodium lauryl sulphate 0.3% 
and 0.5%, apparatus rotating at 50rpm.
FIGURE 4 - The specificity of the method shows apeak of DP 
(A) and excipients solution (B) in thedissolution medium water 
with 0.3% SLS.
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Accuracy and Precision
The recovery measured is typically 95.0-105.0% 
of the drug amount added (FROST, 2004). The accuracy 
of this method was considered adequate in the range 
of 97.85-100.08% for DP (Table II), corroborating the 
accuracy of the method. The intermediate precision 
and repeatability were evaluated at three different 
concentrations of 2.0, 10.0 and 18.0 µg/mL over three 
days, by different analysts. The RSD values are shown 
in (Table III).
Stability of drug in solution and influence of filter 
type
After testing the stability of drug in dissolution 
medium, the drug remained stable in solution for 24 hours 
when stored at room temperature. All results obtained 
during analysis times were very close to the initial value, 
according to (Table IV).
TABLE II - Accuracy of the dissolution method for DP in oral 
suspension




Mean recovery (%) ± SD 
(n = 18)
99.31 ± 1.26 
(95.43 – 103.14)
SD – Standard Deviation
TABLE III - Intermediate precision and repeatability of the 
dissolution method for DP in oral suspension
Intraday (n = 6) Mean value (%) ± SD RSD (%)
day I 101.13 ± 2.49 2.46
day II 97.82 ± 0.94 0.96
day III 98.98 ± 2.04 2.06
Interday (n = 3) 99.31 ± 1.68 1.7
SD – Standard Deviation; RSD – Relative Standard Deviation
TABLE IV -Stability of drugafter dissolution test
Dissolution medium
% Drug Dissolved after test
Time zero After 12 hours After 24 hours RSD (%)
Sample in solution (n =3) 99.65 99.29 99.52 0.18
RSD – Relative Standard Deviation
The filter used was unable to interfere in the 
quantitative analysis of the drug. The sample filtered using 
F. Maia filter (sample A) presented an average content of 
99.42% and the centrifuged sample (sample B), an average 
content of 97.71%, which proves the noninterference of 
the filter used in the tests.
Discrimination power of selected dissolution 
method
Evaluation of dissolution profiles is an important 
tool when it is necessary to know the behavior of 
two products before submitting them to the Study on 
Bioavailability/Bioequivalence, for post-registration 
changes, waiver of in vivo studies of smaller dosages 
as well as optimizing thepharmacotechnical process to 
develop new formulations (Brasil, 2010). The profiles 
were evaluated accordingly (Brasil, 2010), using points 
10, 15 and 30 minutes. Factors f1 and f2 were 2.55 and 
72.65 respectively, coefficient variation was less than 
20.0% for the first points and less than 10.0% for the 
other points, confirming that the profiles obtained between 
batches of pharmaceutical products are similar, according 
to (Figure 5). The results of dissolution profiles for both 
products are given in Table V.
CONCLUSION
A quick, simple dissolution method was successfully 
developed for the evaluation of the in vitro release of DP 
FIGURE 5 – Comparison of profiles of Cataflam® oral suspension 
(n – 12) batches Z0047 and Z0049A, using water with sodium 
lauryl sulphate 0.3% and apparatus rotating at 50 rpm.
A. M. Rubim, J. B. Rubenick, L. V. Laporta, C. M. B. Rolim428
in oral suspension. The conditions used were USP type 
II apparatus at 50 rpm, containing 900 mL of water with 
0.3% SLS, at 37.0 °C ± 0.5. Drug stability was maintained 
under the developed dissolution conditions, and therefore 
the method could be used in routine quality control of DP 
in oral suspension.
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